Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT01464034
Previous Study | Return to List | Next Study

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01464034
Recruitment Status : Active, not recruiting
First Posted : November 3, 2011
Last Update Posted : March 26, 2020
Sponsor:
Collaborators:
Amgen
Celgene Corporation
Information provided by (Responsible Party):
Criterium, Inc.

Brief Summary:
This is a dose finding pilot study to evaluate the safety and determine the maximum tolerated dose of the combination of carfilzomib and pomalidomide with dexamethasone (CPD) in patients with relapsed or refractory multiple myeloma followed by a phase II expansion at the MTD to evaluate efficacy.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Carfilzomib Drug: Pomalidomide Drug: Dexamethasone Phase 1 Phase 2

Detailed Description:
This is a dose finding pilot study to evaluate the safety and determine the maximum tolerated dose of the combination of carfilzomib and pomalidomide with dexamethasone (CPD) in patients with relapsed or refractory multiple myeloma followed by a phase II expansion at the MTD to evaluate efficacy. The study will explore the efficacy of CPD including overall response, time to progression, progression free survival, and time to next therapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 136 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Study Start Date : November 2011
Estimated Primary Completion Date : July 1, 2020
Estimated Study Completion Date : December 2020


Arm Intervention/treatment
Experimental: Carfilzomib, Pomalidomide, Dexamethasone
All eligible subjects will receive the study intervention of Carfilzomib, Pomalidomide, and Dexamethasone.
Drug: Carfilzomib
IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days
Other Name: PR-171

Drug: Pomalidomide
PO daily on Days 1-21, every 28 Days
Other Name: CC-4047

Drug: Dexamethasone
40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.
Other Name: Decadron




Primary Outcome Measures :
  1. Adverse Events as a Measure of Safety and Tolerability [ Time Frame: Throughout treatment, estimated at 2-12 months per patient ]
    Review of adverse events for safety and to determine the maximum tolerated dose of the combination treatment.

  2. Overall Response in Phase II [ Time Frame: Every 28 days while on treatment (estimated at 2- 12 months per patient) ]
    Overall Response (SD, MR, PR, VGPR, CR, sCR)


Secondary Outcome Measures :
  1. Overall Response in Phase I [ Time Frame: Every 28 days while on treatment (estimated at 2- 12 months per patient) ]
    Overall response (SD, MR, PR, VGPR, CR, sCR)

  2. Time to Progression [ Time Frame: Every 28 days while on treatment (estimated at 2-12 months per patient) ]
  3. Progression Free Survival [ Time Frame: throughout follow up (every 2-3 months for 2 years) ]
  4. Time to next therapy [ Time Frame: throughout follow up (every 2-3 months for 2 years) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Cytopathologically or histologically confirmed dx of multiple myeloma
  • Relapsed or refractory to the most recently received therapy.
  • All pts must have received prior lenalidomide therapy and been determined to be refractory, relapsed, or intolerant.
  • Measurable disease, as indicated by one or more of the following:

Serum M-protein ≥ 0.5 g/dL Urine Bence Jones protein ≥ 200 mg/24 hr Elevated Free Light Chain as per IMWG criteria, and abnormal ratio

  • Pts must be ≥ 18 years of age
  • Life expectancy of more than 3 months
  • ECOG PS of 0-2
  • Adequate hepatic function, with bilirubin < 2 times the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 times ULN
  • Uric acid must be within laboratory normal range
  • CrCl ≥ 50 mL/min
  • Additional Laboratory Requirements ANC ≥1.0 x 109/L Hgb ≥8 g/dL(transfusion permitted) Platelet count ≥50.0 x 109/L
  • Screening ANC should be independent of granulocyte-and granulocyte/macrophage colony stimulating factor (G-CSF and GM-CSF) support for at least 1 week and of pegylated G-CSF for at least 2 weeks
  • Pts may receive RBC or platelet transfusions, if clinically indicated, in accordance with institutional guidelines
  • Screening platelet count should be independent of platelet transfusions for at least 2 weeks.
  • Written informed consent in accordance with federal, local, and institutional guidelines
  • FCBP must agree to ongoing pregnancy testing
  • FCBP must have a negative serum or urine pregnancy test and agree to birth control.
  • Male pts must agree to never have unprotected sexual contact with a female who can become pregnant and must agree to either completely abstain from sexual contact with females who are pregnant or are able to become pregnant. The patient must agree to inform his physician if he has had unprotected sexual contact with a female who can become pregnant or if he thinks for any reason that his sexual partner may be pregnant.
  • Male pts cannot donate semen or sperm while taking pomalidomide and for 28 days after completing the study.
  • All pts must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.
  • Pts must agree to take enteric-coated aspirin 81 mg orally daily, or if history of prior thrombotic disease, must be fully anticoagulated with warfarin (INR 2-3) or be treated with full-dose, low molecular weight heparin, as if to treat deep venous thrombosis (DVT)/pulmonary embolism (PE)at the investigator's discretion

Exclusion Criteria:

  • Pts with known sensitivity to any immunomodulatory drugs (IMiDs)
  • Use of any other experimental drug or therapy within 21 days prior to first dose
  • Exposure to any prior chemotherapy, steroid use, or other myeloma treatment within 14 days prior to first dose. Pts currently on long term steroids do not require any washout period. in addition, steroid use for spinal cord compression is permitted and does not require a washout period.
  • Radiation therapy within 14 days prior to first dose
  • Known allergies to carfilzomib or Captisol
  • POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
  • Current diagnosis of plasma cell leukemia
  • Waldenström's macroglobulinemia
  • Major surgery within 21 days prior to first dose
  • Pregnant or lactating females
  • Congestive heart failure (NYHA class III to IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention or myocardial infarction in the previous six months prior to first dose.
  • Uncontrolled hypertension
  • Acute active infection requiring systemic antibiotics, antivirals, or antifungals within 14 days prior to first dose
  • Pts receiving active treatment or intervention for any other malignancy or pts who, at the Investigator's discretion, may require active treatment or intervention for any other malignancy within 8 months of starting study treatment.
  • Serious psychiatric or medical conditions that could interfere with treatment
  • Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the first dose and/or within 14 days before enrollment
  • Contraindication to any of the required concomitant drugs, including proton-pump inhibitor (e.g. lansoprazole), enteric-coated aspirin or if a history of prior thrombotic disease, warfarin or low molecular weight heparin
  • Pts in whom the required program of oral and intravenous fluid hydration is contraindicated, e.g. due to pre-existing pulmonary, cardiac, or renal impairment
  • Pts with primary systemic amyloidosis
  • Pts who have received prior treatment with carfilzomib (Phase II only)
  • Pts who have received prior treatment with pomalidomide (Phase II only)
  • Pts who have received prior treatment with both carfilzomib & pomalidomide (Phase I only)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01464034


Locations
Layout table for location information
United States, Georgia
Winship Cancer Institute of Emory University
Atlanta, Georgia, United States, 30322
United States, Indiana
Indiana University Simon Cancer Center
Indianapolis, Indiana, United States, 46202
United States, New Jersey
The John Theurer Cancer Center @ Hackensack UMC
Hackensack, New Jersey, United States, 07601
United States, New York
Columbia University
New York, New York, United States, 10032
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Pennsylvania
University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania, United States, 19105
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109
Sponsors and Collaborators
Criterium, Inc.
Amgen
Celgene Corporation
Investigators
Layout table for investigator information
Principal Investigator: Jatin Shah, MD AMyC
Principal Investigator: Brian GM Durie, MD AMyC
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Criterium, Inc.
ClinicalTrials.gov Identifier: NCT01464034    
Other Study ID Numbers: AMyC 10-MM-01
IST-CAR-521 ( Other Identifier: Onyx Pharmaceuticals )
PO-MM-PI-0034 ( Other Identifier: Celgene Corporation )
First Posted: November 3, 2011    Key Record Dates
Last Update Posted: March 26, 2020
Last Verified: March 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone
Pomalidomide
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Immunologic Factors
Angiogenesis Inhibitors
Angiogenesis Modulating Agents